Molecular biology of androgen-independent prostate cancer: The role of the androgen receptor pathway

Clinical and Translational Oncology

Volumn 11, Issue 1, 2009, Pages 5-10

  Mellado, Begoña ^a   Codony, Jordi ^a   Ribal, María José ^a   Visa, Laura ^a   Gascón, Pere ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Androgen receptor; Androgen independence; Prostate cancer

Indexed keywords

ABIRATERONE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; B RAF KINASE; BICALUTAMIDE; BMS 641988; CYTOCHROME P450 17; DEPSIPEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; LAPATINIB; MDV 3100; MITOGEN ACTIVATED PROTEIN KINASE; PANOBINOSTAT; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; STEROID RECEPTOR COACTIVATOR 1; TANESPIMYCIN; UNCLASSIFIED DRUG; VORINOSTAT; WNT PROTEIN;

ANDROGEN BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CANCER RESISTANCE; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GENE STRUCTURE; GENE SYNTHESIS; HUMAN; MOLECULAR INTERACTION; PHARMACOLOGICAL BLOCKING; PROSTATE CANCER; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; X CHROMOSOME; DRUG RESISTANCE; GENETICS; MALE; METABOLISM; MOLECULAR BIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVIEW;

ANDROGEN ANTAGONISTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MOLECULAR BIOLOGY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 65349188286     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0304-3     Document Type: Article

References (42)

1. Feldman BF, Feldman D (2001) The development of androgen-independent prostate cancer. Nature Rev 1:34-45
2. Debes JD, Tindall DJ (2004) Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351:1488-1490
3. Scher HI, Sawyers CL (2003) Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor axis. J Clin Oncol 23:8253-8261
4. Chen Yu, Sawyers CL, Scher HI (2008) Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8:440-448
5. Taplin ME (2008) Androgen receptor: Role and novel therapeutic prospects in prostate cancer. Exp Rev Anticancer Ther 8:1495-1508. Review
6. Mohler JL (2008) Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 617:223-234. Review
7. Agoulnik IU, Weigel NL (2008) Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol 617:245-255. Review
8. Centenera MM, Harris JM, Tilley WD, Butler LM (2008) The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol 22:2373-2382. Review
9. Hsieh AC, Small EJ, Ryan CJ (2007) Androgenresponse elements in hormone-refractory prostate cancer: Implications for treatment development. Lancet Oncol 8:933-939. Review
10. Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28:778-808. Review
11. Wang Y, Kreisberg JI, Ghosh PM (2007) Crosstalk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets 7:591-604. Review
12. Tomlins SA, Laxman B, Varambally S et al (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10:177-188
13. Ratliff TL (2005) Mutation of the androgen receptor causes oncogenic transformation of the prostate. J Urol 174:1149
14. Hara T, Miyazaki J, Araki H et al (2003) Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63:149-153
15. Taplin ME, Bubley GJ, Shuster TD et al (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 231:1393-1398
16. Ozers MS, Marks BD, Gowda K et al (2007) The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Biochemistry 46: 683-695
17. Monge A, Jagla M, Lapouge G et al (2006) Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer. Cell Mol Life Sci 63:487-497
18. Marques RB, Erkens-Schulze S, de Ridder CM et al (2005) Androgen receptor modifications in prostate cancer cells upon long-term androgen ablation and antiandrogen treatment. Int J Cancer 117:221-229
19. Taplin ME, Rajeshkumar B, Halabi S et al (2003) Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21:2673-2678
20. Bergerat JP, Céraline J (2008) Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum Mutat Sept 17. [Epub ahead of print]
21. Tomillero A, Moral MA (2008) Gateways to clinical trials. Methods Find Exp Clin Pharmacol 30: 383-408
22. Holzbeierlein J, Lal P, LaTulippe E et al (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen- responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217-227
23. Chen CD, Welsbie DS, Tran C et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39
24. Titus MA, Schell MJ, Lih FB et al (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11:4653-4657
25. Stanbrough M, Bubley GJ, Ross K et al (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815-2825
26. Thomas LN, Douglas RC, Lazier CB et al (2008) Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 53:244-252
27. Montgomery RB, Mostaghel EA, Vessella R et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 68:4447-4454
28. Reid AH, Attard G, Barrie E, de Bono JS (2008) CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 5:610-620
29. Attard G, Reid AH, Yap TA et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563-4571
30. Domingo-Domenech J, Fernandez PL, Filella X et al (2008) Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol 19:269-275
31. Liu Y, Majumder S, McCall W et al (2005) Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 65:3404-3409
32. Gregory CW, Whang YE, McCall W et al (2005) Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 11:1704-1712
33. Whang YE, Moore CN, Armstrong AJ et al (2008) A phase II trial of lapatinib in hormone refractory prostate cancer. J Clin Oncol 26:16037 [Abstract]
34. Jin RJ, Lho Y, Connelly L et al (2008) The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 68:6762-6769
35. Reddy GP, Barrack ER, Dou QP et al (2006) Regulatory processes affecting androgen receptor expression, stability, and function: Potential targets to treat hormone-refractory prostate cancer. Cell Biochem 98:1408-1423
36. Malinowska K, Neuwirt H, Cavarretta I et al (2008) Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer Nov 14. [Epub ahead of print]
37. Seaton A, Scullin P, Maxwell PJ et al (2008) Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 29:1148-1156
38. Robinson DR, Zylstra CR, Williams BO (2008) Wnt signaling and prostate cancer. Curr Drug Targets 9:571-580
39. Wang Y, Kreisberg JI, Ghosh PM (2007) Crosstalk between the androgen receptor and the phosphatidylinositol3-kinase/Akt pathway in prostate cancer. Cancer Drug Targets 7:591-604
40. Solit DB, Scher HI, Rosen N (2003) Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30:709-716
41. Sharifi N, Hurt EM, Farrar WL (2008) Androgen receptor expression in prostate cancer stem cells: Is there a conundrum? Cancer Chemother Pharmacol 62:921-923
42. Maitland NJ, Collins AT (2008) Prostate cancer stem cells: A new target for therapy. J Clin Oncol 26:2862-2870. Review